Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly

Inclusion Criteria: * Aged over 60 years on the day of inclusion. * Informed Consent Form signed. * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances. * Febrile illness (oral temperature ≥ 37.5°C or rectal equivalent temperature ≥ 38.0°C) on the day of inclusion. * Participation in another clinical trial in the four weeks preceding the first trial vaccination. * Planned participation in another clinical trial during the present trial period. * Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy. * Unstable chronic illness (defined as illness requiring hospitalization or a clinically significant change in medication in the 12 weeks prior to inclusion) at a stage that could interfere with trial conduct or completion. * Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures. * Blood or blood-derived products received in the past 3 months. * Any vaccination in the 4 weeks preceding the first trial vaccination. * Vaccination planned in the 4 weeks following the first trial vaccination. * Previous vaccination against influenza (in the previous 6 months) with the trial vaccine or another vaccine. * Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. * Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.